Exenatide in Combination Therapy. Type 2 Diabetes Treatment
Bydureon exenatide or Byetta exenatide are novel GLP-1 (Glucagon-like Peptide-1) incretin mimetic hormone FDA approved for use in type 2 diabetes treatment. Byetta (exenatide) and Bydureon (exenatide) are used in combination therapy to improve blood glucose control in people diagnosed with type 2 diabetes who are taking sulfonylureas, a metformin, a thiazolidinediones (TZDs), a combination of metformin and thiazolidinediones, or a combination of sulfonylureas and metformin.
Exenatide (Byetta) is very good in combination therapy to control blood glucose levels. Exenatide enhances insulin secretion and reducing blood glucose levels as long as person with type 2 diabetes is not sliding into hypoglycemia. This occurs because exenatide (Byetta) promotes food-stimulated insulin secretion from the pancreas in a glucose-dependent fashion. Normal blood glucose levels signal beta cell to diminish release of insulin, and glucagon levels will increase to protect the person with type 2 diabetes against unwelcome hypoglycemia event.
Now, look how wonderful exenatide (Bydureon) works in combination with metformin (Glucophage, Fortamet, or Glumetza) in type 2 diabetes therapy. Combining agents from different therapeutic classes seems to have added benefits in blood glucose control. Metformin acts in type 2 diabetes therapy by decreasing glucose production in the liver, decreasing glucose absorption from food, and increasing
glucose uptake into skeletal muscle. Exenatide (Bydureon) acts by enhancing insulin secretion from the pancreatic beta cell in a glucose-dependent fashion. Exenatide (Bydureon) promotes insulin production and release into the bloodstream where metformin (Glucophage, Glumetza, or Fortamet) uses this insulin to promote glucose uptake by skeletal muscles, in the same time blocking production of glucose in the liver. Perfect combination for type 2 diabetes treatment. When given before meal to a person with type 2 diabetes, exenatide restores first-phase insulin response, reduces postprandial glucagon levels, improves bowel movements, promotes insulin production and release from the pancreas.
The combination therapy of exenatide and pioglitazone has been studied in people with type 2 diabetes. Those who use only exenatide (Bydureon or Byetta injections) had a reduction in fasting plasma glucose levels of 33 mg/dl. But those individuals with type 2 diabetes who used exenatide together with pioglitazone, 30mg, were able to reduce their fasting plasma glucose levels by an average of 73mg/dl.
Another study suggest that combination of exenatide with thiazolidinedione (Avandia or Actos) in type 2 diabetes treatment resulted in that 62 percent of individuals with type 2 diabetes achieve A1C levels of 7 percent or lower, compared with only 16 percent of individuals who doesn’t have Byetta exenatide or Bydureon exenatide in their type 2 diabetes treatment plan. People with type 2 diabetes on combination of exenatide and TZD, Bydureon exenatide plus Actos, or Byetta exenatide plus Avanda TZD, lost, on average, 3.3 pounds of weight over 16 weeks compared to a 0.4 pound weight loss in people with type 2 diabetes on monotherapy.
Exenatide (Byetta) is very powerful help in type 2 diabetes treatment and you can buy it online now. Also, buy Bydureon exenatide online now with prescription.